Homozygous EPM2A mutation (NM_005670.3; c.838 T > G; pTrp280Gly) leads to early-onset parkinsonism and severe neurocognitive decline [46], whereas in-frame deletion of EPM2A slows neurological decline in Lafora disease [47]. Here, EPM2A is linked to Parkinson disease.